费尔西塞特拉格可以刺激人类心房中的5-HT4-色素受体
Lina Maria Rayo Abella1, Joachim Neumann2, Britt Hofmann3
1Institute for Pharmacology and Toxicology, Medical Faculty, Martin-Luther-University Halle-Wittenberg, Magdeburger Straße 4, D-06097, Halle (Saale), Germany.
Naunyn-Schmiedeberg's archives of pharmacology
|September 29, 2025
概括
费尔西塞拉格是一种强大的化合物,向人类的5-HT4受体. 它在哺乳动物心脏制剂中充当激动剂和对抗剂,影响收缩力和心跳率.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管生理学心血管生理学
- 分子生物学分子生物学
背景情况:
- 费尔西塞特拉格具有与血清素的结构相似性.
- 它是人类重组5-HT4受体的高强度连接体.
研究的目的:
- 研究felcisetrag对心脏5-HT4受体的功能影响.
- 为了确定felcisetrag是否在哺乳动物心脏组织中起到agonist或antagonist的作用.
主要方法:
- 在小鼠心房制剂 (5-HT4-TG和WT) 和人类心房制剂 (HAP) 中评估心脏收缩性和心跳率.
- 利用GR125487,一种5-HT4受体对抗剂,以及胺胺来调节受体活性.
- 检查了单独和与血清素结合使用的felcisetrag的影响.
主要成果:
- 费尔西塞拉格在过度表达5-HT4受体的小鼠心脏中增加了收缩力和心跳率,GR125487阻止了这些效应.
- 在人类心房制剂中,费尔西塞拉格仅在基洛斯塔米德时引起了积极的内效应,GR125487.减弱了这种效应.
- 费尔西塞拉格在血清素存在时,在人类5-HT4受体上表现出双重激素和抗活性.
结论:
- 在哺乳动物心脏中的人类5-HT4受体上,Felcisetrag表现出复杂的药理学.
- 该化合物可以作为5-HT4受体的激动剂和抗剂,这取决于实验条件.
相关概念视频
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
849
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
849
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
01:30Transducer Mechanism: G Protein–Coupled Receptors
3.8K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
3.8K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K
01:21G-protein Coupled Receptors
131.3K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
131.3K